Harnessing CAR-T Therapy for Hematologic Malignancies and Solid Tumors: Experience from City of Hope

Register free: http://www.appliedclinicaltrialsonline.com/act_w/hematology

Event Overview:
Cellular therapy promises dramatic advances in oncology, harnessing the immune system itself to fight cancer.  And although CAR-T cell therapy has seen most of its success in blood cancers, there is progress and promise on the solid tumor front as well.

In this exclusive webcast, cutting-edge researchers from the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Cancer Center-Elizabeth Budde, MD, PhD and Saul Price, PhD-share their most recent experiences reprogramming T cells with chimeric antigen receptors (CARs) to tackle both hematologic and solid tumors.  

They will conclude with a Question & Answer session, moderated by Al Blunt, MD, Senior Vice President, Precision for Medicine. 

Key Learning Objectives:

Attendees will get expert insights regarding:

• Overview of adoptive therapy using CAR-engineered T cells, with details on key variables in CAR design, adoptive transfer, and T-cell isolation, activation, and expansion 

• Details of T-cell therapy research at City of Hope to treat brain metastases, solid tumors, and hematological cancers 

• Future research foci, including reverse translation, overcoming tumor antigen escape, and improving T-cell persistence in challenging tumors

Speakers: Dr. Elizabeth Budde, Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope

Dr. Saul Priceman, Ph.D., Assistant Professor, City of Hope

Dr. Al Blunt, MD, Senior VP, Medical – Americas, Precision for Medicine

Time and date: Wednesday, Jun. 24, 2020 at 12pm EDT | 1pm CDT | 9am PDT

On demand available after airing until Jun. 24, 2021.

Sponsor: Precision for Medicine

Register free: http://www.appliedclinicaltrialsonline.com/act_w/hematology